Billings, MT - January 26, 2026 - PRESSADVANTAGE - Patients seeking expert care for glaucoma in the region are turning ...
CEDAR RAPIDS, IA - January 27, 2026 - PRESSADVANTAGE - As cases of glaucoma continue to rise across the United States, ...
Sleeping without pillows may help lower high internal eye pressure, build-up of which causes optic nerve damage and ...
DF-003 is the first ALPK1 inhibitor to successfully complete a first-in-human Phase 1 study and has now entered a Phase 1b clinical trial in patients with ROSAH syndrome (NCT06395285), where it is ...
Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
A diagnosis of uveal melanoma marks the beginning of a long-term relationship with your medical team. While the focus starts ...
Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing in the registrational PIONEER program across 2 key ...
Morning Overview on MSN
New study flags powerful drug target that could transform glaucoma treatment
Glaucoma has long been treated as a plumbing problem of the eye, managed mainly by lowering pressure rather than protecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results